Headquartered in San Francisco, CA·Fiscal year ends December·NASDAQ: NKTR·nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company developing treatments that target the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin (REZPEG, NKTR-358), is a first-in-class regulatory T cell (Treg) stimulator now in Phase 3 development. Three global ZENITH AD registrational trials are underway in moderate-to-severe atopic dermatitis, and the ZENITH AA registrational trial in alopecia areata is set to start in December 2026. REZPEG is also being evaluated in Type 1 diabetes mellitus. The preclinical pipeline includes the bivalent TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166 and a modified hematopoietic colony stimulating factor protein, NKTR-422. Current revenue is non-cash royalty revenue related to previously sold future royalty streams. The company also holds an equity-method investment in Gannet BioChem. It funds R&D from a cash and investment balance of about $952.9 million, built up through equity raises in 2026. Updated
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Monday's additional top analyst upgrades and downgrades were on Coinbase Global, Global Blood Therapeutics, Grab, Leslie’s, Nektar Therapeutics, Park Hotels & Resorts, Rocket Companies and Roku.
Tuesday’s additional top analyst upgrades and downgrades included Dow, Estee Lauder, Magellan Midstream Partners, Nektar Therapeutics, Novo Nordisk, Rocket Companies, Sherwin-Williams, Steel Dynamics and Zoom Video Communications.
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Wednesday afternoon's top analyst upgrades and downgrades included Bumble, Coupang, Foot Locker, Gap, Match, Nektar Therapeutics, Paychex, Signify Health and Stitch Fix.
Tuesday's top analyst upgrades and downgrades included Airbnb, Canopy Growth, Continental Resources, DraftKings, Fisker, Moderna, Owens Corning, SunPower and Wayfair.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
Wednesday's top analyst upgrades, downgrades and initiations included Altria, Beyond Meat, Chevron, Chipotle Mexican Grill, Epizyme, FedEx, Home Depot, Mattel, Morgan Stanley, Oracle, Qualcomm and Target.
Nektar Therapeutics is a clinical-stage biotechnology company developing treatments that target the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
What is the NKTR stock price target?
The Wall Street consensus 12-month price target for NKTR is $131.92.